Telix Pharmaceuticals (TLX) Competitors

Telix Pharmaceuticals (NASDAQ:TLX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Do insiders and institutionals believe in TLX or GMAB?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has stronger valuation & earnings, TLX or GMAB?

Genmab A/S has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$516.72M	8.17	$32.93M	N/A	N/A
Genmab A/S	$3.12B	5.06	$1.14B	$1.99	12.39

Do analysts prefer TLX or GMAB?

Telix Pharmaceuticals currently has a consensus price target of $22.33, indicating a potential upside of 78.95%. Genmab A/S has a consensus price target of $37.60, indicating a potential upside of 52.54%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media refer more to TLX or GMAB?

In the previous week, Telix Pharmaceuticals had 8 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Telix Pharmaceuticals and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.70 beat Telix Pharmaceuticals' score of 0.35 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is TLX or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Telix Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Genmab A/S	37.53%	21.03%	16.98%

Summary

Genmab A/S beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.